Our company
Technology
Biotech/Pharma
Applications
Resources
Investors
Contact us

Resources

Therapeutic areas

All Autoimmune diseases General Immuno-oncology Infectious diseases News Partnerships Uncategorised

Diseases

Systemic lupus erythematosus (SLE) Sjörgen’s syndrome Systemic sclerosis (SSc) Rheumatoid arthritis (RA)

Checkpoint inhibitors Bispecifics CAR-T CART-NK EarlyCDT Lung Cancer

COVID19 Long-Covid

Filter by type

annual report

autoantibodies

Brochure

cancer

checkpoint inhibitors

Company News

company update

Diagnostics

immunotheraphies

Indeterminate Pulmonary Nodules

Poster

Publication

Webinar

ImmunoINSIGHTS Platform

Paradoxical sex-specific patterns of autoantibodies response to SARS-CoV-2 infection

Novel biomarkers of immunotherapy outcomes and immune-related adverse events

Autoantibodies as Biomarkers in Immuno-oncology

POSTER: Multiplexed Autoantibody Profiling Of Patients With Metastatic Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors Or Platinum-Based Chemotherapy (Oncimmune Collaboration), ASCO Genitourinary Cancers Symposium 2022

Oncimmune receives Queen’s Award for Enterprise in Innovation 2022

Oncimmune signs contracts with US-based clinical-stage biopharmaceutical companies developing immunotherapies one of which is focused on CAR NK cell therapies.

Follow-on contract signed with leading US medical research organisation, to validate previous profiling in COVID-19

ImmunoINSIGHTS and Synexa Life Sciences sign go-to-market service partnership

28 February 2022

POSTER: Autoantibody Profiling in Prostvac and Ipilimumab Treated Prostate Cancer Patients Reveals Potential Biomarkers of Immune-Related Adverse Events

Understanding diseases through the lens of the human immune system.

Company Overview
About ImmunoINSIGHTS™
Biomarker Discovery
Targeted Panels & Arrays
Publications
Contact us
Privacy Policy
Terms of Use
Cookies Policy

© Oncimmune Holdings PLC. Registered England and Wales. Number 09818395.